Ifosfamide plus doxorubicin in metastatic adult sarcomas

a multi-institutional phase II trial

Patrick Loehrer, G. W. Sledge, C. Nicaise, J. Usakewicz, J. D. Hainsworth, O. J. Martelo, G. Omura, T. J. Braun

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin. The majority of patients had leiomyosarcoma and malignant fibrous histiocytoma although two patients with sarcomas of osseous origin were included. Doxorubicin was administered at a dosage of 60 mg/m2 by continuous push and ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna (7.5 g2 over 36 hours) with courses repeated every 3 weeks until progression, toxicity cumulative doxorubicin dosage of 450 mg/m2. Overall, 15 (36%) patients demonstrated objective remissions including three complete and 12 partial remissions (95% confidence limits, 21.5% to 52.0%). The median duration of remission was 7.0 months and the median survival time for all eligible patients was 8.0 months. Toxicity was predominantly hematologic with the median leukocyte nadir being 1,300 per microliter of blood and documented sepsis in six patients. These data support activity for ifosfamide plus doxorubicin in patients with advanced sarcoma, but the actual contribution of ifosfamide needs to be evaluated through prospective randomized trials which are currently underway.

Original languageEnglish
Pages (from-to)1655-1659
Number of pages5
JournalJournal of Clinical Oncology
Volume7
Issue number11
StatePublished - 1989

Fingerprint

Ifosfamide
Sarcoma
Doxorubicin
Mesna
Malignant Fibrous Histiocytoma
Leiomyosarcoma
Sepsis
Leukocytes
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loehrer, P., Sledge, G. W., Nicaise, C., Usakewicz, J., Hainsworth, J. D., Martelo, O. J., ... Braun, T. J. (1989). Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. Journal of Clinical Oncology, 7(11), 1655-1659.

Ifosfamide plus doxorubicin in metastatic adult sarcomas : a multi-institutional phase II trial. / Loehrer, Patrick; Sledge, G. W.; Nicaise, C.; Usakewicz, J.; Hainsworth, J. D.; Martelo, O. J.; Omura, G.; Braun, T. J.

In: Journal of Clinical Oncology, Vol. 7, No. 11, 1989, p. 1655-1659.

Research output: Contribution to journalArticle

Loehrer, P, Sledge, GW, Nicaise, C, Usakewicz, J, Hainsworth, JD, Martelo, OJ, Omura, G & Braun, TJ 1989, 'Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial', Journal of Clinical Oncology, vol. 7, no. 11, pp. 1655-1659.
Loehrer P, Sledge GW, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. Journal of Clinical Oncology. 1989;7(11):1655-1659.
Loehrer, Patrick ; Sledge, G. W. ; Nicaise, C. ; Usakewicz, J. ; Hainsworth, J. D. ; Martelo, O. J. ; Omura, G. ; Braun, T. J. / Ifosfamide plus doxorubicin in metastatic adult sarcomas : a multi-institutional phase II trial. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 11. pp. 1655-1659.
@article{dd656faf789643cd8b8c3336449d3dbe,
title = "Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial",
abstract = "Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin. The majority of patients had leiomyosarcoma and malignant fibrous histiocytoma although two patients with sarcomas of osseous origin were included. Doxorubicin was administered at a dosage of 60 mg/m2 by continuous push and ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna (7.5 g2 over 36 hours) with courses repeated every 3 weeks until progression, toxicity cumulative doxorubicin dosage of 450 mg/m2. Overall, 15 (36{\%}) patients demonstrated objective remissions including three complete and 12 partial remissions (95{\%} confidence limits, 21.5{\%} to 52.0{\%}). The median duration of remission was 7.0 months and the median survival time for all eligible patients was 8.0 months. Toxicity was predominantly hematologic with the median leukocyte nadir being 1,300 per microliter of blood and documented sepsis in six patients. These data support activity for ifosfamide plus doxorubicin in patients with advanced sarcoma, but the actual contribution of ifosfamide needs to be evaluated through prospective randomized trials which are currently underway.",
author = "Patrick Loehrer and Sledge, {G. W.} and C. Nicaise and J. Usakewicz and Hainsworth, {J. D.} and Martelo, {O. J.} and G. Omura and Braun, {T. J.}",
year = "1989",
language = "English",
volume = "7",
pages = "1655--1659",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Ifosfamide plus doxorubicin in metastatic adult sarcomas

T2 - a multi-institutional phase II trial

AU - Loehrer, Patrick

AU - Sledge, G. W.

AU - Nicaise, C.

AU - Usakewicz, J.

AU - Hainsworth, J. D.

AU - Martelo, O. J.

AU - Omura, G.

AU - Braun, T. J.

PY - 1989

Y1 - 1989

N2 - Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin. The majority of patients had leiomyosarcoma and malignant fibrous histiocytoma although two patients with sarcomas of osseous origin were included. Doxorubicin was administered at a dosage of 60 mg/m2 by continuous push and ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna (7.5 g2 over 36 hours) with courses repeated every 3 weeks until progression, toxicity cumulative doxorubicin dosage of 450 mg/m2. Overall, 15 (36%) patients demonstrated objective remissions including three complete and 12 partial remissions (95% confidence limits, 21.5% to 52.0%). The median duration of remission was 7.0 months and the median survival time for all eligible patients was 8.0 months. Toxicity was predominantly hematologic with the median leukocyte nadir being 1,300 per microliter of blood and documented sepsis in six patients. These data support activity for ifosfamide plus doxorubicin in patients with advanced sarcoma, but the actual contribution of ifosfamide needs to be evaluated through prospective randomized trials which are currently underway.

AB - Between April 1986 and March 1987, 42 patients with advanced sarcoma were entered in this multi-institutional trial evaluating ifosfamide plus doxorubicin. The majority of patients had leiomyosarcoma and malignant fibrous histiocytoma although two patients with sarcomas of osseous origin were included. Doxorubicin was administered at a dosage of 60 mg/m2 by continuous push and ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna (7.5 g2 over 36 hours) with courses repeated every 3 weeks until progression, toxicity cumulative doxorubicin dosage of 450 mg/m2. Overall, 15 (36%) patients demonstrated objective remissions including three complete and 12 partial remissions (95% confidence limits, 21.5% to 52.0%). The median duration of remission was 7.0 months and the median survival time for all eligible patients was 8.0 months. Toxicity was predominantly hematologic with the median leukocyte nadir being 1,300 per microliter of blood and documented sepsis in six patients. These data support activity for ifosfamide plus doxorubicin in patients with advanced sarcoma, but the actual contribution of ifosfamide needs to be evaluated through prospective randomized trials which are currently underway.

UR - http://www.scopus.com/inward/record.url?scp=0024461340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024461340&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1655

EP - 1659

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -